AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03428009 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Study interventions are minimal risk.
Study NCT03781518 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ridge splitting in group and khoury shell technique in the other group
Description: Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
Study NCT03781518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge splitting in group and khoury shell technique in the other group
Description: Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
Study NCT04051892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FixNip™ NRI
Description: The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
Study NCT03119103 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Functional Bed Sheet
Description: All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
Study NCT04015661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
Study NCT04015661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
Study NCT00851175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 7 day treatment with rosuvastatin 1dd 20mg
Study NCT00851175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: 7 day treatment with rosuvastatin 1dd 20mg
Study NCT00851175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine
Description: intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
Study NCT01379365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Touch III
Description: Percutaneous treatment with the device
Study NCT02957461 — intervention group
Intervention type: DEVICE
Intervention: BrainScope Ahead 200iD
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.
Study NCT01620606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy & Social Learning
Description: Cognitive Behavioral Therapy \& Social Learning
Study NCT01620606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Support
Description: Education about the GI system, nutrition and food safety
Study NCT04596852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch
Description: Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability.
Study NCT01548456 — intervention group
Intervention type: PROCEDURE
Intervention: Intramedullary Nailing
Description: Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
Study NCT01548456 — intervention group
Intervention type: PROCEDURE
Intervention: Open Reduction Internal Fixation
Description: Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
Study NCT04605471 — intervention group
Intervention type: DRUG
Intervention: Iopromide(Ultravist, BAY86-4877)
Description: The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
Study NCT03159611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoten for children
Description: Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
Study NCT03159611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
Study NCT00162981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam Low Dose
Description: 5 to 10 mg/day with doses in the morning and at bedtime; orally
Study NCT02058368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5mg capsules
Description: Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
Study NCT02058368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride placebo capsules
Description: Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
Study NCT02058368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2mg tablets
Description: Commercially available tamsulosin 0.2mg tablets will be supplied.
Study NCT00162981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam High Dose
Description: 5 to 40 mg/day with doses in the morning and at bedtime; orally
Study NCT00505713 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
Study NCT00505713 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study NCT00505713 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study NCT00505713 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study NCT00505713 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study NCT01408290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FAB-3511
Description: One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
Study NCT01408290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FAB-6011
Description: One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
Study NCT01408290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FAB-9011
Description: One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
Study NCT03198611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Usual echocardiographic studies in patients suffering septic shock
Study NCT01347203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPOC-4088
Description: A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
Study NCT01347203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPOC-4088
Description: A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
Study NCT01347203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPOC-4088
Description: A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
Study NCT01347203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPOC-4088
Description: A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
Study NCT02284997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGDRx® EyeBag
Description: Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
Study NCT02460198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT04645212 — intervention group
Intervention type: BIOLOGICAL
Intervention: ADVM-022
Description: Long term follow-up of subjects that received ADVM-022
Study NCT03449303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EOI
Description: Topically-applied oil
Study NCT03449303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topically-applied oil
Study NCT04315285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill gait training with verbal instruction
Description: Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
Study NCT04315285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill gait training with verbal instruction
Description: Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
Study NCT00993213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care with Liposuction
Description: Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
Study NCT00993213 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care without Liposuction
Description: Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
Study NCT01886794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postmenopausal, topical vaginal estrogen cream
Description: Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
Study NCT01886794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Postmenopausal, topical placebo cream
Description: Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
Study NCT01408290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FluvalAB
Description: One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
Study NCT04150575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10+Albumin-Bound Paclitaxel
Description: HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
Study NCT03403634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO
Study NCT03403634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03403634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV
Study NCT03403634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV
Study NCT01997775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METFORMIN
Description: Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 > 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
Study NCT03058406 — intervention group
Intervention type: DRUG
Intervention: Eribulin mesylate
Description: Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
Study NCT00363987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketosteril®
Description: 1 tablet Ketosteril/5kgBW/d
Study NCT00363987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diabetic diet
Description: Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
Study NCT00821691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amantadin
Description: Amantadin caps
Study NCT00821691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo caps
Study NCT02058368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disintegrating placebo tamsulosin tablet
Description: Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
Study NCT00917059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Fixed dose of 10 mg per day
Study NCT04272099 — intervention group
Intervention type: OTHER
Intervention: Administration of standardized questionnaires
Description: Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy
Study NCT00917059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion XL
Description: Fixed dose of 150 mg per day
Study NCT01879397 — intervention group
Intervention type: DEVICE
Intervention: Research Ultrasound Exam
Description: Collection of backscattered ultrasound data during non-invasive ultrasound exam~* ARFI based images of the carotid artery and plaque~* Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam.
Study NCT01871948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: We Want to Know campaign, Patient survey at 2 time points
Description: Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
Study NCT03864497 — intervention group
Intervention type: PROCEDURE
Intervention: Myocardial perfusion imaging
Study NCT02605590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR DNase
Study NCT02605590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03765281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigation
Description: Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
Study NCT03765281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resource List
Description: Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
Study NCT03765281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resource List
Description: Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
Study NCT03110159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan® Kerastick®
Description: Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
Study NCT03110159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-U Blue Light Photodynamic Therapy
Description: 3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
Study NCT06038682 — intervention group
Intervention type: DRUG
Intervention: Argatroban Injection
Description: Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
Study NCT06038682 — intervention group
Intervention type: DRUG
Intervention: Heparin
Description: Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
Study NCT04401228 — intervention group
Intervention type: OTHER
Intervention: predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?
Description: patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact \< one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded
Study NCT01431508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg / HCTZ 12.5 mg
Description: Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
Study NCT01700816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
Study NCT01700816 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham light
Description: The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
Study NCT01092195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: 3 separate 0.5 ml intramuscular
Study NCT02032446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)
Description: pentostatin, dose 1 mg/m2~§ MSC doses:~1. 3 patients → 3 infusions of 1x106 cells /kg~2. 3 patients → 3 infusions of 2x106 cells /kg~3. 3 patients → 3 infusions of 3x106 cells /kg
Study NCT04272099 — intervention group
Intervention type: DEVICE
Intervention: Physical activity tracker
Description: PG1 will be asked to wear a physical activity tracker for one week to monitor activity patterns including walking distance, calorie expenditure, sedentary time and sleep.
Study NCT04272099 — intervention group
Intervention type: OTHER
Intervention: Dietary log
Description: PG1 (or PG2 as proxies when appropriate) will report to a study coordinator via phone a full dietary log of PG1 once per week on rotating days of the week for three weeks.